Table 1.
Clinicopathological characteristics of the Mannheim cohort (overall and respective subgroups). KRT, keratin; L, lymphovascular invasion; V, blood vessel invasion; R, resection margin; WHO, World Health Organization; n.s., not significant; G, Grade; T, Tumor. * p-Value a: KRT5high vs. KRT5low; p-value b: KRT20high vs. KRT20low.
| Characteristic | Total | KRT5 High | KRT5 Low | KRT20 High | KRT20 Low | p-Value |
|---|---|---|---|---|---|---|
| Cohort size (n) | 122 | 89 | 33 | 48 | 74 | |
| Mean age (years) | 67.9 | 67.9 | 68.4 | 67.5 | 67.9 | a: n.s. b: n.s. |
| Gender (n) | ||||||
| Male | 89 (73%) | 66 (74%) | 23 (70%) | 34 (71%) | 55 (74%) | a: n.s. |
| Female | 33 (27%) | 23 (26%) | 10 (30%) | 14 (29%) | 19 (26%) | b: n.s. |
| Adjuvant chemotherapy | 22 (18%) | 14 (16%) | 8 (24%) | 9 (19%) | 13 (17%) | n.s. |
| Pathological characteristics | ||||||
| pTis (concomitant) | 43 (35%) | 34 (38%) | 9 (27%) | 19 (40%) | 24 (32%) | a: n.s. b: n.s. |
| pT2 | 33 (27%) | 28 (31%) | 5 (15%) | 14 (29%) | 19 (26%) | a: 0.027 |
| pT3 | 62 (51%) | 44 (50%) | 18 (55%) | 25 (52%) | 37 (50%) | b: n.s. |
| pT4 | 27 (22%) | 17 (19%) | 10 (30%) | 9 (19%) | 18 (24%) | |
| pN0 | 74 (60%) | 60 (67%) | 14 (42%) | 20 (42%) | 54 (73%) | a: 0.0005 |
| pN1-2 | 48 (37%) | 29 (33%) | 19 (57%) | 28 (58%) | 20 (27%) | b: 0.002 |
| L0 | 62 (51%) | 52 (58%) | 10 (30%) | 17 (35%) | 45 (61%) | a: 0.005 |
| L1 | 60 (49%) | 37 (52%) | 23 (70%) | 31 (65%) | 29 (39%) | b: 0.006 |
| V0 | 104 (85%) | 81 (91%) | 23 (70%) | 42 (87%) | 61 (84%) | a: 0.005 |
| V1 | 18 (15%) | 8 (9%) | 10 (30%) | 6 (13%) | 12 (16%) | b: n.s. |
| R0 | 105 (86%) | 77 (86%) | 28 (85%) | 42 (88%) | 63 (85%) | a: n.s. |
| R1 | 17 (14%) | 12 (14%) | 5 (15%) | 6 (12%) | 11 (15%) | b: n.s. |
| Grading | ||||||
| WHO 1973 | ||||||
| G1 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| G2 | 27 (22%) | 21 (24%) | 6 (18%) | 11 (23%) | 16 (22%) | a: n.s. |
| G3 | 95 (78%) | 68 (76%) | 27 (82%) | 37 (77%) | 58 (78%) | b: n.s. |
| WHO 2004 | ||||||
| Low grade | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | a: n.s. |
| High grade | 122 (100%) | 89 (100%) | 33(100%) | 48 (100%) | 74 (100%) | b: n.s. |
| Characteristic | Epi-Typer Class 1 | Epi-Typer Class 2 | p-Value | |||
| Cohort size (n) | 103 | 19 | ||||
| Mean age (years) | 67.9 | 71 | n.s. | |||
| Gender (n) | ||||||
| Male | 75 (73%) | 14 (74%) | n.s. | |||
| Female | 28 (27%) | 5 (26%) | ||||
| Adjuvant chemotherapy | 17 (17%) | 5 (26%) | n.s. | |||
| Pathological T stage | ||||||
| pTis (concomitant) | 37 (36%) | 6 (31%) | n.s. | |||
| pT2 | ||||||
| pT3 | ||||||
| pT4 | ||||||
| Pathological characteristics | ||||||
| pN0 | 69 (67%) | 5 (26%) | 0.0009 | |||
| pN1-2 | 34 (33%) | 14 (74%) | ||||
| L0 | 58 (56%) | 4 (21%) | 0.004 | |||
| L1 | 45 (44%) | 15 (79%) | ||||
| V0 | 90 (87%) | 14 (74%) | n.s. | |||
| V1 | 13 (13%) | 5 (26%) | ||||
| R0 | 89 (86%) | 16 (84%) | n.s. | |||
| R1 | 14 (14%) | 3 (16%) | ||||
| Grading WHO 1973 | ||||||
| G1 | 0 (0%) | 0 (0%) | n.s. | |||
| G2 | 22 (21%) | 5 (26%) | n.s. | |||
| G3 | 81 (79%) | 14 (74%) | n.s. | |||
| Grading WHO 2004 | ||||||
| Low grade | 0 (0%) | 0 (0%) | n.s. | |||
| High grade | 103 (100%) | 19 (100%) | n.s. | |||
Distribution of clinic-pathological determinants across the entire cohort and respective subgroups. p-value a: KRT5high vs. KRT5low; p-value b: KRT20high vs. KRT20low.